Testing for the CCR5 Δ32 mutation in clinical practice might be useful for elucidation of the reason for delayed progression of HIV infection, however it should probably not influence decision on antiretroviral treatment initiation or modification. This evidence concerns the gene CCR5 and HIV infectious disease.